-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology:3D Organoid Platform Function Introduction
Author:
InnoModels
Release time:
2024-04-16
With the rapid development of biotechnology, 3D organoid technology has gradually emerged as a new favorite in biomedical research. In this field, the 3D organoid platform of InnoModels Biotechnology has opened the door to real human physiology and disease mechanisms for researchers with its excellent key functions.
First of all, the 3D organoid platform of InnoModels Biotechnology has excellent simulation capability. While traditional two-dimensional cell culture models often fail to fully simulate the complex environment of the real human body, 3D organoid technology is capable of constructing three-dimensional tissue structures that are closer to the real thing, thus more accurately simulating the physiological and pathological processes in the human body. This feature enables researchers to study the occurrence, development and treatment of diseases more realistically in an in vitro environment, improving the accuracy and reliability of research.
Secondly, 3D organoid platform of InnoModels Biotechnology is highly customizable. Different tissues and organs have unique structures and functions, while the 3D organoid platform of InnoModels is able to customize organoid models with specific structures and functions according to the needs of researchers. This customizability allows researchers to build the most suitable organoid models for specific research goals, thus improving research efficiency and results.

In addition, the 3D organoid platform from InnoModels Biotechnology is equipped with high-throughput processing capabilities. While traditional cell culture models often face time, space and resource constraints when processing large numbers of samples, the 3D organoid platform is able to process multiple samples at the same time through highly efficient production processes and technical means, thus greatly increasing the throughput of research. This high-throughput processing capability enables researchers to obtain a large amount of experimental data in a short period of time, accelerating the progress of research and the output of results.
Finally, the 3D organoid platform of InnoModels Biotechnology also has a wide range of application prospects. Whether in drug discovery, disease modeling or regenerative medicine, 3D organoid technology shows great potential and value. By constructing organoid models with specific structures and functions, researchers are able to gain a deeper understanding of the mechanisms and developmental processes of diseases, and thus develop more accurate and effective therapeutic methods. At the same time, 3D organoid technology can also provide important tools and resources to support regenerative medicine and promote the regeneration and repair of human tissues and organs.
In summary, 3D organoid platform of InnoModels Biotechnology has become an important tool in the field of biomedical research with its excellent simulation capability, high customizability, high-throughput processing capability and wide application prospects. With the continuous development and innovation of the technology, it is believed that the 3D organoid platform will bring more breakthroughs and surprises to researchers to promote the development and progress of the biomedical field.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd